WallStSmart

AbbVie Inc (ABBV)vsNovo Nordisk A/S (NVO)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Novo Nordisk A/S generates 405% more annual revenue ($333.65B vs $66.01B). NVO leads profitability with a 33.9% profit margin vs 15.7%. ABBV appears more attractively valued with a PEG of 0.59. ABBV earns a higher WallStSmart Score of 77/100 (B+).

ABBV

Strong Buy

77

out of 100

Grade: B+

Growth: 6.7Profit: 9.0Value: 4.0Quality: 5.0
Piotroski: 5/9Altman Z: 0.40

NVO

Buy

59

out of 100

Grade: C

Growth: 6.0Profit: 10.0Value: 5.7Quality: 5.0
Piotroski: 3/9Altman Z: 2.13
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABBVSignificantly Overvalued (-79.8%)

Margin of Safety

-79.8%

Fair Value

$157.70

Current Price

$286.20

$128.50 premium

UndervaluedFair: $157.70Overvalued

Intrinsic value data unavailable for NVO.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABBV6 strengths · Avg: 9.7/10
Market CapQuality
$520.47B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
62.3%10/10

Every $100 of equity generates 62 in profit

Operating MarginProfitability
36.6%10/10

Strong operational efficiency at 36.6%

EPS GrowthGrowth
2282.0%10/10

Earnings expanding 2282.0% YoY

Debt/EquityHealth
-17.6510/10

Conservative balance sheet, low leverage

PEG RatioValuation
0.598/10

Growing faster than its price suggests

NVO6 strengths · Avg: 9.8/10
P/E RatioValuation
10.2x10/10

Attractively priced relative to earnings

Return on EquityProfitability
52.0%10/10

Every $100 of equity generates 52 in profit

Profit MarginProfitability
33.9%10/10

Keeps 34 of every $100 in revenue as profit

Operating MarginProfitability
40.1%10/10

Strong operational efficiency at 40.1%

Free Cash FlowQuality
$28.10B10/10

Generating 28.1B in free cash flow

Market CapQuality
$177.74B9/10

Large-cap with strong market position

Areas to Watch

ABBV2 concerns · Avg: 2.0/10
P/E RatioValuation
50.6x2/10

Premium valuation, high expectations priced in

Altman Z-ScoreHealth
0.402/10

Distress zone — elevated risk

NVO3 concerns · Avg: 2.3/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
4.482/10

Expensive relative to growth rate

EPS GrowthGrowth
-15.8%2/10

Earnings declined 15.8%

Comparative Analysis Report

WallStSmart Research

Bull Case : ABBV

The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 15.7% and operating margin at 36.6%. Revenue growth of 10.3% demonstrates continued momentum.

Bull Case : NVO

The strongest argument for NVO centers on P/E Ratio, Return on Equity, Profit Margin. Profitability is solid with margins at 33.9% and operating margin at 40.1%.

Bear Case : ABBV

The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 50.6x leaves little room for execution misses.

Bear Case : NVO

The primary concerns for NVO are Piotroski F-Score, PEG Ratio, EPS Growth.

Key Dynamics to Monitor

NVO carries more volatility with a beta of 0.37 — expect wider price swings.

ABBV is growing revenue faster at 10.3% — sustainability is the question.

NVO generates stronger free cash flow (28.1B), providing more financial flexibility.

Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ABBV scores higher overall (77/100 vs 59/100), backed by strong 15.7% margins and 10.3% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

AbbVie Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.

Novo Nordisk A/S

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novo Nordisk A / S, a healthcare company, is dedicated to the research, development, manufacture and marketing of pharmaceutical products globally. The company is headquartered in Bagsvaerd, Denmark.

Want to dig deeper into these stocks?